The Ascletis boss wants the biotech start-up to develop its own world-class drugs
Related Posts
China Tech Digest: Pony.ai Plans to Launch Robotaxi in U.S. in 2022; Hangzhou Established a RMB20 Billion Biomedical Industry Fund
Kiwi columnist for Shanghai Daily celebrates his ‘China state-affiliated media’ label on Twitter
Chinese professor raises $ 3.4 billion in assets with SenseTime’s IPO
Apple is giving engineers in China more responsibility over manufacturing processes
Goodwill Thunder reappears! With provision for impairment of 740 million yuan, the target goodwill returned to zero, and Jincheng Pharmaceutical shareholders frequently reduced their holdings in Finance
Honor discusses the future of foldables, on-device AI, and PWM displays
Central banks look to China’s renminbi to diversify foreign currency reserves
Hong Kong protesters break into government building- Heavy retail trading lures quant funds to China markets
China hails crushing of salmon-smuggling ‘syndicate’